雷替曲塞联合伊立替康治疗晚期结肠癌患者的疗效及安全性

目的探讨雷替曲塞联合伊立替康治疗晚期结肠癌患者的疗效及安全性。方法选取2018年1月至2019年12月沈阳市肛肠医院收治的50例晚期结肠癌患者作为研究对象,按治疗方案不同分为对照组与观察组,各25例。对照组采用伊立替康、5-氟尿嘧啶和亚叶酸钙治疗,观察组给予伊立替康联合雷替曲塞治疗,比较两组治疗效果及安全性。结果观察组治疗有效率92.0%,高于对照组的68.0%,差异有统计学意义(P<0.05)。观察组不良反应发生率20.0%低于对照组40.0%,差异有统计学意义(P<0.05)。观察组生存时间长于对照组,差异有统计学意义(P<0.05)。两组治疗前糖类抗原199(CA199)、癌胚抗原(CEA)水平比较,差异无统计学意义(P>0.05);治疗后观察组CA199、CEA水平低于对照组,差异有统计学意义(P<0.05)。结论针对晚期结肠癌患者采用雷替曲塞联合伊立替康治疗,可获得更加满意的疗效,安全性良好。

Efficacy and Safety Analysis of Raltitrexed Combined with Irinotecan in the Treatment of Patients with Advanced Colon Cancer

Objective To explore the efficacy and safety of raltitrexed combined with irinotecan in the treatment of advanced colon cancer. Methods A total of 50 patients with advanced colon cancer admitted Shenyang Anorectal Hospital from January 2018 to December 2019 were selected as the research objects and were divided into a control group and an observation group according to the different treatment methods. The control group was given irinotecan, 5-FU and Leucovorin. The observation group was treated with irinotecan combined with raltitrexed, and the therapeutic effect and safety of the 2 groups were compared. Results The effective rate of treatment in the observation group was 92.0%, which was higher than 68.0% in the control group, and the difference was statistically significant(P<0.05). The incidence of adverse reactions in the observation group was 20.0% lower than that in the control group 40.0%, and the difference was statistically significant(P<0.05). The survival time of the observation group was longer than that of the control group, and the difference was statistically significant(P<0.05). There was no significant difference in the levels of carbohydrate antigen 199(CA199) and carcinoembryonic antigen(CEA) between the 2 groups before treatment(P>0.05);after treatment, the levels of CA199 and CEA in the observation group were lower than those in the control group, and the difference was statistically significant(P<0.05). Conclusion The treatment of raltitrexed combined with irinotecan for patients with advanced colon cancer can have a more satisfactory curative effect and good safety.